{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:24:32Z","timestamp":1792787072395,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":2138,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Aspen Pharmaceuticals"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1111\/jth.13563","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T03:19:09Z","timestamp":1478315949000},"page":"74-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Continuation of low\u2010molecular\u2010weight heparin treatment for cancer\u2010related venous thromboembolism: a prospective cohort study in daily clinical practice"],"prefix":"10.1016","volume":"15","author":[{"given":"S.J.","family":"van der Wall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Klok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"den Exter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Morillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Cannegieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13563_bb0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13563_bb0015","doi-asserted-by":"crossref","first-page":"I17","DOI":"10.1161\/01.CIR.0000078466.72504.AC","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/jth.13563_bb0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1111\/jth.13563_bb0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low\u2010molecular\u2010weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13563_bb0030","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1111\/jth.13563_bb0035","first-page":"Cd006650","article-title":"Anticoagulation for the long\u2010term treatment of venous thromboembolism in patients with cancer","volume":"7","author":"Akl","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/jth.13563_bb0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4037\/ajcc1996.5.4.271","article-title":"Effect of syringe size on bruising following subcutaneous heparin injection","volume":"5","author":"Hadley","year":"1996","journal-title":"Am J Crit Care"},{"key":"10.1111\/jth.13563_bb0045","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13563_bb0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180\u2010day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.13563_bb0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1160\/TH12-03-0169","article-title":"Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study","volume":"108","author":"Kahn","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13563_bb0060","first-page":"3369","article-title":"Adherence to treatment guidelines for cancer\u2010associated thrombosis: a French hospital\u2010based cohort study","volume":"8","author":"Mahe","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1111\/jth.13563_bb0065","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000380871","article-title":"Treatment of venous thromboembolism in ambulatory cancer patients in Germany: a prospective non\u2010interventional study","volume":"38","author":"Matzdorff","year":"2015","journal-title":"Oncol Res Treat"},{"key":"10.1111\/jth.13563_bb0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.thromres.2012.12.004","article-title":"Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study","volume":"131","author":"Rahme","year":"2013","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13563_bb0075","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.12605","article-title":"Meta\u2010analysis of the efficacy and safety of new oral anticoagulants in patients with cancer\u2010associated acute venous thromboembolism","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13563_bb0080","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/jth.12124","article-title":"Diagnostic management of acute deep vein thrombosis and pulmonary embolism","volume":"11","author":"Huisman","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13563_bb0085","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non\u2010surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13563_bb0090","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/jth.12825","article-title":"Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality","volume":"13","author":"Ay","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13563_bb0095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta\u2010analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13563_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2013.11.001","article-title":"Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants","volume":"28","author":"Wharin","year":"2014","journal-title":"Blood Rev"},{"key":"10.1111\/jth.13563_bb0105","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1160\/TH15-06-0452","article-title":"Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE\u2010cancer study","volume":"114","author":"van Es","year":"2015","journal-title":"Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13563","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13563","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622031658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622031658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13563\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:17:09Z","timestamp":1761535029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622031658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1538783622031658"],"URL":"https:\/\/doi.org\/10.1111\/jth.13563","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuation of low\u2010molecular\u2010weight heparin treatment for cancer\u2010related venous thromboembolism: a prospective cohort study in daily clinical practice","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}